• Explore /
  • Poster
  • / FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Abstract Poster

Authors

null

Vincent J. Picozzi

Virginia Mason Medical Center, Seattle, WA

Vincent J. Picozzi , J. Marc Pipas , Albert Koong , Amato Giaccia , Nathan Bahary , Smitha S. Krishnamurthi , Charles D. Lopez , Peter J. O'Dwyer , Katharina Modelska , Mairead Carney , Heather Hernandez , James Chou , Tyson Lee , Ming Zhong , Seth Porter , Tom Neff , Frank Valone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01181245

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4138)

DOI

10.1200/jco.2014.32.15_suppl.4138

Abstract #

4138

Poster Bd #

225

Abstract Disclosures

Similar Posters

First Author: Vincent Picozzi

First Author: Gang Jin

Poster

2020 Gastrointestinal Cancers Symposium

Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.

Prognostic utility of inflammation biomarkers in a PDAC trial involving the human anti-CTGF antibody pamrevlumab.

First Author: Mark D. Sternlicht

First Author: Li-Tzong Chen